menu
    • menu
    [{"orgOrder":0,"company":"Universit\u00e4tsklinikum Hamburg-Eppendorf","sponsor":"Therakos | University Medical Center Regensburg | Arbeitskreis Klinische Forschung PD Dr. med. Seiler GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Methoxsalen","moa":"DNA","graph1":"Immunology","graph2":"Phase II","graph3":"Universit\u00e4tsklinikum Hamburg-Eppendorf","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universit\u00e4tsklinikum Hamburg-Eppendorf \/ Therakos | University Medical Center Regensburg | Arbeitskreis Klinische Forschung PD Dr. med. Seiler GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Universit\u00e4tsklinikum Hamburg-Eppendorf \/ Therakos | University Medical Center Regensburg | Arbeitskreis Klinische Forschung PD Dr. med. Seiler GmbH"},{"orgOrder":0,"company":"CVC Capital Partners","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"LUXEMBOURG","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Methoxsalen","moa":"DNA","graph1":"Immunology","graph2":"Phase II","graph3":"CVC Capital Partners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CVC Capital Partners \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CVC Capital Partners \/ Undisclosed"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"CVC Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Methoxsalen","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0.93000000000000005,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.93000000000000005,"dosageForm":"Undisclosed","sponsorNew":"Mallinckrodt Pharmaceuticals \/ CVC Capital Partners","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ CVC Capital Partners"},{"orgOrder":0,"company":"London Health Sciences Centre Research Institute (Lawson)","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Methoxsalen","moa":"DNA","graph1":"Dermatology","graph2":"Phase II","graph3":"London Health Sciences Centre Research Institute (Lawson)","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"London Health Sciences Centre Research Institute (Lawson) \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"London Health Sciences Centre Research Institute (Lawson) \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"Immunolight","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Methoxsalen","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Immunolight","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Immunolight \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immunolight \/ Undisclosed"},{"orgOrder":0,"company":"Columbia University","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Methoxsalen","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Columbia University \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Columbia University \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Methyltyrosine","moa":"||Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tyme Technologies \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Syros Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Merger","leadProduct":"Methyltyrosine","moa":"||Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Capsule","sponsorNew":"Tyme Technologies \/ Syros Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Technologies \/ Syros Pharmaceuticals"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Methyltyrosine","moa":"||Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Capsule","sponsorNew":"Tyme Technologies \/ Eagle Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Technologies \/ Eagle Pharmaceuticals"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Methyltyrosine","moa":"||Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tyme Technologies \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Methyltyrosine","moa":"||Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tyme Technologies \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Methyltyrosine","moa":"||Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tyme Technologies \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Methyltyrosine","moa":"||Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tyme Technologies \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Methyltyrosine","moa":"||Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tyme Technologies \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Methyltyrosine","moa":"||Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tyme Technologies \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Syros Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Private Placement","leadProduct":"Methyltyrosine","moa":"||Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0.13,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"Capsule","sponsorNew":"Tyme Technologies \/ Syros Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Technologies \/ Syros Pharmaceuticals"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Methyltyrosine","moa":"||Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase II","graph3":"Tyme Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tyme Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tyme Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Methyltyrosine","moa":"||Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tyme Technologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tyme Technologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tyme Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Methyltyrosine","moa":"||Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase II","graph3":"Tyme Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tyme Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tyme Technologies \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Methoxsalen

    Menu

    Methoxsalen

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CVC Capital Partners

                            Country arrow
                            The Battery Show
                            Not Confirmed

                            CVC Capital Partners

                            Country arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methoxsalen

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis

                            Details : Methoxsalen is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 17, 2024

                            Lead Product(s) : Methoxsalen

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Mallinckrodt Pharmaceuticals

                            Ireland arrow
                            The Battery Show
                            Not Confirmed

                            Mallinckrodt Pharmaceuticals

                            Ireland arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methoxsalen

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : CVC Capital Partners

                            Deal Size : $925.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Mallinckrodt Reaches Agreement to Sell Therakos® Business to CVC for $925 Million

                            Details : Through the acquisition, CVC will leverage the Company's Therakos Uvadex (methoxsalen), a fully integrated ECP delivery system for skin manifestations of Cutaneous T-cell lymphoma.

                            Product Name : Uvadex

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 05, 2024

                            Lead Product(s) : Methoxsalen

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : CVC Capital Partners

                            Deal Size : $925.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Columbia University

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed

                            Columbia University

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methoxsalen

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Mallinckrodt Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Photopheresis in Early-stage Mycosis Fungoides

                            Details : Methoxsalen is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma, T-Cell, Cutaneous.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 11, 2023

                            Lead Product(s) : Methoxsalen

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Mallinckrodt Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Tyme Technologies

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed

                            Tyme Technologies

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methyltyrosine,Methoxsalen,Phenytoin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Syros Pharmaceuticals

                            Deal Size : $130.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement

                            Details : SM-88 (racemetyrosine) is an orally administered cancer metabolism-based therapy that is chemically altered to be non-functional for fundamental tumor cell processes, including protein synthesis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 16, 2022

                            Lead Product(s) : Methyltyrosine,Methoxsalen,Phenytoin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Syros Pharmaceuticals

                            Deal Size : $130.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Tyme Technologies

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed

                            Tyme Technologies

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methyltyrosine,Methoxsalen,Phenytoin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Syros Pharmaceuticals

                            Deal Size : $60.0 million

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placeme...

                            Details : In the merger, Syros expects to issue approximately 74.3 million shares of its common stock to TYME stockholders to acquire TYME’s pipeline including SM-88 (D/L-alpha-metyrosine).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 05, 2022

                            Lead Product(s) : Methyltyrosine,Methoxsalen,Phenytoin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Syros Pharmaceuticals

                            Deal Size : $60.0 million

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Tyme Technologies

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed

                            Tyme Technologies

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methyltyrosine,Methoxsalen,Phenytoin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TYME Technologies, Inc. Announces SM-88 Poster at the American Association for Cancer Research (AACR) Annual M...

                            Details : The results that SM-88 alone showed antiproliferative effects in each of the sensitive and resistant cells lines, and that the combination of SM-88 and MPS had an additive effect in these models.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 09, 2022

                            Lead Product(s) : Methyltyrosine,Methoxsalen,Phenytoin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Tyme Technologies

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed

                            Tyme Technologies

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methyltyrosine,Methoxsalen,Phenytoin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TYME Technologies, Inc. Provides Update on Precision Promise Trial in Metastatic Pancreatic Cancer

                            Details : SM-88 (D/L-alpha-metyrosine), with MPS arm of Phase 2/3 platform trial in metastatic pancreatic cancer discontinued for futility on primary endpoint of overall survival.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 26, 2022

                            Lead Product(s) : Methyltyrosine,Methoxsalen,Phenytoin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Immunolight

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed

                            Immunolight

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methoxsalen

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Recruiting Patients for Phase 1 Trial of the X-PACT System in Solid Tumors

                            Details : The heart of the X-PACT system is 8-MOP (also known as 8-methoxypsoralen or methoxsalen) which has been successfully used for decades in the treatment of autoimmune disease, skin disorders and certain skin and blood cancers.

                            Product Name : X-PACT System

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 16, 2021

                            Lead Product(s) : Methoxsalen

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            London Health Sciences Centre Research Institute (Lawson)

                            Country arrow
                            The Battery Show
                            Not Confirmed

                            London Health Sciences Centre Research Institute (Lawson)

                            Country arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methoxsalen

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Mallinckrodt Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis

                            Details : Uvadex (Methoxsalen) is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Scleroderma, Diffuse.

                            Product Name : Uvadex

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 03, 2021

                            Lead Product(s) : Methoxsalen

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Mallinckrodt Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Tyme Technologies

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed

                            Tyme Technologies

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methyltyrosine,Methoxsalen,Phenytoin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tyme Granted U.S. Patent Claims Covering Use of Tyrosine-Based Drug Delivery Method to Treat Cancer

                            Details : SM-88 is an oral investigational modified proprietary tyrosine derivative that interrupt the metabolic processes of cancer cells by breaking down the cells’ key defenses and leading to cell death through oxidative stress and exposure to the body’s na...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 26, 2021

                            Lead Product(s) : Methyltyrosine,Methoxsalen,Phenytoin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth